Prospective Registration Of Patient Data and Quality of Life in Eye Melanoma Patients

Launched by LEIDEN UNIVERSITY MEDICAL CENTER · May 11, 2022

Keywords

ClinConnect Summary

The PROQEM trial is a study that aims to understand how living with uveal melanoma, a type of eye cancer, affects patients' quality of life both before and for five years after they receive treatment. Researchers are looking to gather important information from patients about their experiences during this time, which can help improve care and support for others with the same condition.

To be eligible for this study, participants need to be at least 18 years old and have been diagnosed with melanoma in specific parts of the eye. They also must not have any signs that the cancer has spread, confirmed through tests like a chest X-ray, blood tests, and an ultrasound of the liver. Patients will receive treatments such as brachytherapy (a type of radiation therapy), proton therapy, or possibly have their eye removed (enucleation). By joining this trial, participants will contribute valuable information that could help improve future treatments and support for those facing uveal melanoma.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥18 years
• • Clinical or pathological diagnosis of a melanoma of the choroid or ciliary body
• • No signs of metastasis after staging procedures with at least an X-thorax, blood test and an ultrasound of the liver
• • Treatment by brachytherapy, proton therapy or enucleation
• Exclusion Criteria:
• • None